ArticleThe Journal of clinical endocrinology and metabolism2025
Evaluation of Sleep Health in Children With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucocorticoid reduction after starting crinecerfont in pediatric patients with classic congenital adrenal hyperplasia: practical perspectives.The Journal of clinical endocrinology and metabolism · 2026Review
- Evaluation of Sleep Health in Children With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.The Journal of clinical endocrinology and metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
contextLiterature on sleep health in children with congenital adrenal hyperplasia (CAH) is sparse despite the important role the hypothalamic-pituitary-adrenal axis plays in sleep onset, duration, and awakenings after sleep onset.
objectiveTo evaluate sleep health in children and adolescents with CAH as measured by wrist actigraphy and validated sleep questionnaires.
methodsCross-sectional study at our multidisciplinary CAH clinic. Participants aged 3 to 18 years with classic CAH wore an ActiGraph GT3X+ accelerometer for 1 week. Children and parents completed sleep questionnaires, and the results were compared to published samples from the community and children with sleep disorders (clinical). Actigraphy sleep health measures were compared to consensus sleep duration recommendations and normative data in healthy children.
resultsForty-four participants (23 male) with CAH completed the study. Actigraphy found sleep duration in children with CAH was less than recommended guidelines with significantly worse sleep efficiency and increased wake after sleep onset (P < .05) compared to healthy children. After sleep onset, the average number of awakenings increased from 1.67 per hour during the first 2 hours after the evening hydrocortisone dose to 3.12 per hour 4 to 7 hours after the dose, corresponding with washout of the evening hydrocortisone dose. Parents of 3- to 10-year-olds reported significantly worse sleep onset delay and decreased sleep duration than both the community and clinical samples, and significantly more night awakenings than the community sample.
conclusionOur findings suggest that sleep health is impaired in children with CAH and is an important consideration for both clinical practice and future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.